InMode Ltd vs Global X Uranium ETF — how do they compare? InMode Ltd trades at $15.25 (market cap $872.08M), while Global X Uranium ETF trades at $45.1. The key difference: InMode Ltd is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals.
| INMD | URA | |
|---|---|---|
Market Cap | $872.08M | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $16.62 | $61.81 |
52-Week Low | $12.76 | $36.45 |
Enterprise Value | $375.42M | — |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.23, up 0.26% today, with a neutral technical outlook and mixed earnings history including a Q1 2026 miss. The company reported Q2 2026 revenue of $95.6 million, consistent year-over-year, and maintains a strong gross profit margin of 76.52%. Recent news highlights an unsolicited acquisition offer from Steel Partners at $16.75 per share and shareholder activism urging rejection, creating uncertainty around corporate governance.
The stock presents a value opportunity with low P/E and EV/EBITDA ratios, but risks include earnings volatility, potential acquisition fallout, and ongoing securities fraud investigations. Analyst consensus is divided between Buy and Hold ratings, reflecting cautious optimism amid near-term headwinds. Long-term growth depends on execution of international expansion and innovation in medical technologies.
URA, the Global X Uranium ETF, trades at $45.20, up 1.85% on the day, with a bullish technical signal from moving averages and strong buying pressure indicated by ADX. The ETF benefits from positive sentiment around nuclear energy demand driven by AI power needs and government support, including a recent $17.5 billion U.S. loan commitment for new reactors. However, RSI levels suggest potential overbought conditions near-term.
The outlook for URA is positive due to structural tailwinds in nuclear energy, but risks include ETF expense ratios and uranium price volatility. Investor sentiment is bolstered by index expansions and geopolitical deals, yet the fund lacks traditional valuation metrics as it holds diversified uranium-related equities rather than operating as a single company.
Trailing returns across standard periods
Latest headlines on both assets
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →